## Cellular pathology audit template

|  |  |
| --- | --- |
| Date of completion  | (To be inserted when completed) |
| Name of lead author/participants | (To be inserted) |
| Specialty | Neuropathology |
| Title | **Audit of reporting of central nervous system tumours in adults, including the pituitary gland** |
| Background | Datasets published by the Royal College of Pathologists define the core data items that should be included in histopathology reports to ensure all necessary data is provided.In 2024, the College’s *Dataset for histopathological reporting of tumours of the central nervous system in adults, including the pituitary gland* was published, which lists and discusses the data items to be included when reporting anal biopsy specimens.1 |
| Aim & objectives | This audit template is a tool to determine whether reporting of adult central nervous system (CNS) and pituitary tumours meets with standards as outlined in the RCPath document |
| Standards & criteria | **Criteria range:** 100%, or if not achieved, there is documentation in the case notes that explains the variance.1. Core data items are included in reports – as detailed in COSD and this dataset and relevant to tumour type.
2. Turnaround times and local targets are met.
 |
| Method | **Sample selection:** (To be completed by the author)All cases of … within the time period from … to … All adult CNS tumour types/specific tumour type (state……… e.g. meningioma/PNET) auditedSpecimen received and date report authorised. **Data to be collected on proforma (see below).** |
| Results | (To be completed by the author)The results of this audit show the following compliance with the standards.

|  |  |
| --- | --- |
| **Data items** | % compliance |
| **Clinical information on pathology report:**NameSexAge/DoBNHS numberHospital numberLab numberDate of surgeryReceipt of sampleSurgeonDate of reportPathologistTumour location/sideNeuroimaging featuresPrevious diagnosis and/orPrevious treatmentType of procedure: biopsy/ lobectomy, etc. |  |
| Intraoperative smear reporting times / report included in main histology reportArchiving of frozen samples |  |
| **Macroscopic report includes**Colour/consistencyDimensions or weightNumber of samples |  |
| **Histology report**Adequacy of specimen for diagnosisHistological description (see dataset for tumour type/WHO 2021 for entities)Histological grade as appropriate (CNS WHO classification)Relationship to other tissues/invasion (for some tumour types, e.g. meningioma)SNOMED codeIntegrated final diagnosis (see ICCR dataset) |  |
| Reporting turnaround times for histology report |  |
| Reported turnaround time for molecular report / integrated diagnosis |  |

**Commentary:** |
| Conclusion | (To be completed by the author) |
| Recommend-ations for improvement | Present the result with recommendations, actions and responsibilities for action and a timescale for implementation. Assign a person(s) responsible to do the work within a timeframe.**Some suggestions:**highlight areas of practice that are differentpresent findings. |
| Action plan | (To be completed by the author – see attached action plan proforma) |
| Re-audit date | (To be completed by the author) |
| Reference | 1. Royal College of Pathologists. *Dataset for histopathological reporting of tumours of the central nervous system in adults, including the pituitary gland.* Accessed October 2024. Available at: [https://www.rcpath.org/profession/guidelines/cancer-datasets-and-tissue-pathways.html#](https://www.rcpath.org/profession/guidelines/cancer-datasets-and-tissue-pathways.html)
 |

## Data collection proforma for reporting of central nervous system tumours in adults, including the pituitary gland

## Audit reviewing practice

Patient name:

Hospital number:

Date of birth:

Consultant:

Case number:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Standards** | **1****Yes**  | **2****No** | **3** If no, was there documentation to explain the variance? **Yes/No** plus free-text comment | **4** Compliant with guideline based on **Yes** from column 1 or an appropriate explanation from column 3. **Yes/No** |
| **Clinical information on pathology report:**NameSexAge/DoBNHS numberHospital numberLab numberDate of surgeryReceipt of sampleSurgeonDate of reportPathologistTumour location/sideNeuroimaging featuresPrevious diagnosis and/orPrevious treatmentType of procedure: biopsy/lobectomy etc. |  |  |  |  |
| Intraoperative smear reporting times/report included in main histology reportArchiving of frozen samples |  |  |  |  |
| **Macroscopic report includes**Colour/consistencyDimensions or weightNumber of samples |  |  |  |  |
| **Histology report**Adequacy of specimen for diagnosisHistological description (see dataset for tumour type/WHO 2021 for entities)Histological grade as appropriate (CNS WHO classification)Relationship to other tissues/invasion (for some tumour types, e.g. meningioma)SNOMED codeIntegrated final diagnosis (see ICCR dataset) |  |  |  |  |
| Reporting turnaround times for histology report |  |  |  |  |
| Reported turnaround time for molecular report/integrated diagnosis |  |  |  |  |

|  |
| --- |
| **Audit action plan** Audit of reporting of central nervous system tumours in adults, including the pituitary gland |
| Audit recommendation | Objective | Action | Timescale | Barriers and constraints | Outcome | Monitoring |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |